Unknown PHASE2 INTERVENTIONAL 1-arm NCT04514393

Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma

Phase II Study of Combination Treatment of Methotrexate, Ibrutinib, and Temozolomide (MIT Regimen) in Patients With Newly Diagnosed Primary CNS Lymphoma

Sponsor: Guangdong 999 Brain Hospital

Conditions Non Hodgkin Lymphoma PCNSL Primary Central Nervous System Lymphoma

Interventions Ibrutinib Methotrexate Temozolomide

Updated 6 times since 2020 Last updated: Apr 6, 2022 Started: Oct 10, 2020 Primary completion: Sep 1, 2022 Completion: Jun 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04514393, this PHASE2 trial focuses on Non Hodgkin Lymphoma and PCNSL and remains ongoing. Sponsored by Guangdong 999 Brain Hospital, it has been updated 6 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Jul 2023 — Jul 2024 [monthly]

Recruiting PHASE2
May 2022 — Jul 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2021 — May 2022 [monthly]

Not Yet Recruiting PHASE2

▶ Show 1 earlier version

Sep 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangdong 999 Brain Hospital
Huiqiang Huang
Nanfang Hospital, Southern Medical University
Xian-Janssen Pharmaceutical Ltd.

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guandong, China
• Guangzhou, China